Increasing the production of insulin glargine in Pichia pastoris through medium modification [PDF]
BIO Web of ConferencesInsulin is the primary drug for managing diabetes mellitus, especially for individuals with type 1 diabetes mellitus. Producing insulin glargine, a long-acting insulin analogue, using Pichia pastoris is a notable advancement in biopharmaceutical ...
Hardianto Dudi +7 more
doaj +2 more sources
Insulin glargine 300 U/ml in the management of diabetes: clinical utility and patient perspectives [PDF]
Patient Preference and Adherence, 2016 Bastiaan E de Galan Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands Abstract: There is ongoing interest in optimizing basal insulin treatment by developing insulins with a flat pharmacological profile, a ...
de Galan BE
doaj +3 more sources
Diabetes, Metabolic Syndrome and Obesity, 2011 Shinya Abe1,2, Gaku Inoue1,2, Satoru Yamada1,3, Junichiro Irie1,3, Hiroyuki Nojima2, Kaoru Tsuyusaki2, Kensuke Usui2, Koichiro Atsuda2, Toshikazu Yamanouchi41Diabetes Center, Kitasato Institute Hospital, 2Center for Clinical Pharmacy and Clinical ...
Abe S +8 more
doaj +1 more source
Insulin glargine in the treatment of type 1 and type 2 diabetes 59
Vascular Health and Risk Management, 2006 Anthony H BarnettBirmingham Heartlands Hospital, Birmingham, West Midlands, England, UKAbstract: Insulin glargine is an analogue of human insulin that is modified to provide a consistent level of plasma insulin over a long duration.
Anthony H Barnett
doaj +1 more source
Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes
Vascular Health and Risk Management, 2015 Joshua J Joseph, Thomas W Donner Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA Abstract: Cardiovascular disease is the leading cause of mortality in type 2 ...
Joseph JJ, Donner TW
doaj +1 more source
Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE). [PDF]
Diabetes Obes MetabABSTRACT Aims Type 2 diabetes (T2D) management with basal insulin can lead to hypoglycaemia and weight gain. SUSTAIN OPTIMIZE compared once‐weekly semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine (Sema+IGlarreduced) versus dose‐titrated IGlar (IGlartitrated) on glycated haemoglobin (HbA1c), body weight (BW), daily insulin dose, and ...
Rodbard HW +7 more
europepmc +2 more sources
Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes [PDF]
, 2004 Objectives: To assess the clinical and cost-effectiveness of continuous subcutaneous insulin infusion (CSII) compared with multiple daily injections (MDI) in the delivery of intensive insulin therapy for the treatment of diabetes mellitus.
Green, C. +9 more
core +1 more source
Insulin glargine affects the expression of Igf-1r, Insr, and Igf-1 genes in colon and liver of diabetic rats [PDF]
Iranian Journal of Basic Medical Sciences, 2018 Objective(s): The mitogenic effect of the analogous insulin glargine is currently under debate since several clinical studies have raised the possibility that insulin glargine treatment has a carcinogenic potential in different tissues.
Clara I Juárez-Vázquez +8 more
doaj +1 more source
Cancer risk associated with insulin glargine among adult type 2 diabetes patients--a nationwide cohort study. [PDF]
PLoS ONE, 2011 BACKGROUND: Preclinical and observational studies raise the concern about the safety of insulin glargine in terms of cancer initiation and promotion.
Chia-Hsuin Chang +6 more
doaj +1 more source
Clinical Diabetology, 2021 Background. Basal-bolus insulin therapy is the most widely accepted method of glycemic control in non-critically ill patients with T2DM. In this regimen glargine U100 is the most commonly used basal insulin.
Asis Mitra, Saswati Ray, Sushma Jayan
doaj +1 more source